Abstract
Non-alcoholic fatty liver disease (NAFLD) is one of the most common diseases worldwide, affecting more than 30% of general population. High-fat diets, physical inactivity and obesity, all prevalent in the western societies, are strongly associated with the development and progression of NAFLD. Current drug therapies have not consistently shown substantial beneficial effects. Thus, lifestyle modification appears to be the optimal intervention in combating the disease. Accordingly, several studies have concluded that weight loss, via increase in physical activity, and dietary interventions could potential ameliorate biochemical, histological, and structural abnormalities of non-alcoholic fatty liver disease. The aim of this review is to summarize the findings of these lifestyle intervention studies and discuss the implementation of each intervention, and its effectiveness in the management of the disease in everyday clinical practice.
Keywords: Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, lifestyle modification, weight loss, physical activity, nutrition, diet.
Current Vascular Pharmacology
Title:Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non- Alcoholic Steatohepatitis
Volume: 16 Issue: 3
Author(s): Konstantinos Stavropoulos, Konstantinos Imprialos, Andreas Pittaras, Charles Faselis, Puneet Narayan and Peter Kokkinos*
Affiliation:
- VAMC and Georgetown University, School of Medicine, Washington, DC,United States
Keywords: Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, lifestyle modification, weight loss, physical activity, nutrition, diet.
Abstract: Non-alcoholic fatty liver disease (NAFLD) is one of the most common diseases worldwide, affecting more than 30% of general population. High-fat diets, physical inactivity and obesity, all prevalent in the western societies, are strongly associated with the development and progression of NAFLD. Current drug therapies have not consistently shown substantial beneficial effects. Thus, lifestyle modification appears to be the optimal intervention in combating the disease. Accordingly, several studies have concluded that weight loss, via increase in physical activity, and dietary interventions could potential ameliorate biochemical, histological, and structural abnormalities of non-alcoholic fatty liver disease. The aim of this review is to summarize the findings of these lifestyle intervention studies and discuss the implementation of each intervention, and its effectiveness in the management of the disease in everyday clinical practice.
Export Options
About this article
Cite this article as:
Stavropoulos Konstantinos , Imprialos Konstantinos, Pittaras Andreas, Faselis Charles , Narayan Puneet and Kokkinos Peter*, Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non- Alcoholic Steatohepatitis, Current Vascular Pharmacology 2018; 16 (3) . https://dx.doi.org/10.2174/1570161115666170621080835
DOI https://dx.doi.org/10.2174/1570161115666170621080835 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dyslipidaemia, Hypercoagulability and the Metabolic Syndrome
Current Vascular Pharmacology Contribution of ALDH2 Polymorphism to Alcoholism-Associated Hypertension
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Effect of Polyphenolic Compounds from Solanum torvum on Plasma Lipid Peroxidation, Superoxide anion and Cytochrome P450 2E1 in Human Liver Microsomes
Medicinal Chemistry Aldosterone to Renin Ratio (ARR) in Clinical use, with Reference to the Primary Care Setting: ARR to Whom, When, How, What for?
Current Hypertension Reviews Nanotechnology and Atherosclerosis Imaging: Emerging Diagnostic and Therapeutic Applications
Recent Patents on Cardiovascular Drug Discovery Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Optimal Management of Hypertension in patients with Ischemic Heart Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Combination of Fenofibrate with Non-Statin Drug Regimens
Current Pharmaceutical Design Modulation of Energy Intake and Expenditure Due to Habitual Physical Exercise
Current Pharmaceutical Design Engineering of Nanospheres Dispersed Microneedle System for Antihypertensive Action
Current Drug Delivery Effects of Hyperlipidemia and Cardiovascular Diseases on Proliferation, Differentiation and Homing of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Molecular Function of Tocopherols in Age Related Diseases
Current Pharmaceutical Design Endothelin Receptor Antagonists: An Overview of Their Synthesis and Structure-Activity Relationship
Mini-Reviews in Medicinal Chemistry Cognitive Impairment with Vascular Impairment and Degeneration
Current Neurovascular Research IgA Nephropathy: Clinical Significance of Urinary Proteins/Polypeptides Characterization
Current Proteomics Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design The Role of Angiotensin Type 1 Receptor in Inflammation and Endothelial Dysfunction
Recent Patents on Cardiovascular Drug Discovery Relationship Among Adherence to the Mediterranean Diet and Anthropometric and Metabolic Parameters in Subjects with Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets Myocardial Perfusion SPECT Imaging in Patients after Coronary Revascularization
Vascular Disease Prevention (Discontinued) The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis
Current Vascular Pharmacology